Lorna Nicholas
Lorna has more than 15 years' experience as a business/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.
Frontier Energy locks-in water supply in critical milestone for Bristol Springs renewable energy project
Frontier Energy (ASX: FHE) has reached a critical milestone after locking-in a binding water supply agreement to underpin green hydrogen production at its Bristol Springs renewable energy project, in Western Australia’s South West. Under the deal with Western Australian Government-owned Water Corporation, Frontier will be able to use up to 1,250 kilolitres of water a […]
Sayona Mining and Piedmont Lithium receive final permit to restart NAL operation
Sayona Mining (OTCQB: SYAXF) and joint venture partner Piedmont Lithium (NASDAQ: PLL) have locked-in the final permit required to restart the North American Lithium (NAL) mine and concentrator in Quebec, with first spodumene production expected early next year. Sayona owns 75% of NAL via joint venture subsidiary Sayona Quebec, while Piedmont holds the remaining 25% plus a […]
Incannex Healthcare’s IHL-42X lowered apnea hypopnea index score in OSA sufferers during clinical study
Incannex Healthcare (NASDAQ: IXHL, ASX: IHL) has found its drug IHL-42X reduced the apnea hypopnea index (AHI) score at the three doses it was given to obstructive sleep apnea (OSA) patients during a phase 2 clinical trial. Incannex developed IHL-42X with two primary pharmaceutical ingredients tetrahydrocannabinol (THC) and acetazolamide to target different aspects of OSA. […]
Incannex Healthcare closes in on completing APIRx Pharmaceuticals acquisition
Incannex Healthcare (ASX: IHL) has completed the share sale and purchase agreement to acquire APIRx Pharmaceuticals, which will form “the world’s largest portfolio” of patented medicinal cannabinoid (CBD) drugs and psychedelic treatments. Under the deal, APIRx stakeholders will receive almost 218.17 million Incannex shares at $0.573 each once the acquisition has been officially completed, which […]